Login

Recent searches

No recent searches

Search options

Only available when logged in.
wandering.shop is one of the many independent Mastodon servers you can use to participate in the fediverse.
Wandering.Shop aims to have the vibe of a quality coffee shop at a busy SF&F Convention. Think tables of writers, fans and interested passers-by sharing drinks and conversation on a variety of topics.

Administered by:

Server stats:

879
active users

wandering.shop: AboutProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.3.5

#oncology

4 posts3 participants0 posts today
Public
Newsramp

Canada Royal Enoch Phytomedicine's Redsenol-1 Plus gains NCI Drug Dictionary recognition, highlighting breakthrough ginsenoside supplement with potential cancer-related fatigue solution. Innovative research leads the way in natural health innovations. #Oncology #Innovation

Newsramp Image
Public *
ScienceOpen

'Utility of Assessing Early Tumor Shrinkage as an Efficacy Predictor in Patients with Non-Surgically Indicated or Recurrent Esophageal Cancer Treated with Nivolumab plus Ipilimumab' - an #Oncology article by Karger Publishers on #ScienceOpen:
scienceopen.com/document?vid=8

ScienceOpenUtility of Assessing Early Tumor Shrinkage as an Efficacy Predictor in Patients with Non-Surgically Indicated or Recurrent Esophageal Cancer Treated with Nivolumab plus Ipilimumab<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d3734252e235"> <b> <i>Introduction:</i> </b> Nivolumab plus ipilimumab combination therapy has been administered as a first-line treatment in Japan since 2022 for patients with unresectable progressive or recurrent esophageal cancer. The efficacy and safety of this immune checkpoint inhibitor (ICI) doublet therapy are now being evaluated, and it is necessary to identify populations that benefit from this treatment at an early phase after initiation. For patients not showing early benefit, changing as soon as possible to other therapeutic strategies could improve their survival outcomes. Therefore, we attempted to identify decision-making factors such as early tumor shrinkage (ETS) based on treatment experience with ICI doublet therapy. <b> <i>Methods:</i> </b> The study included 19 patients who received nivolumab plus ipilimumab for non-surgically indicated or recurrent esophageal cancer between July 2022 and November 2023. Tumors were assessed approximately every 2 months after treatment initiation. The effects of ETS, depth of response (DpR), and clinicopathologic features, including immune-related adverse events (irAEs), on progression-free and overall survival were evaluated using Kaplan-Meier plots and Cox proportional hazard models. <b> <i>Results:</i> </b> The mean duration of ICI doublet administration was 5.89 months (range, 1–16 months). At first evaluation, patients who exhibited no tumor progression >20% indicated possible response to ICI doublet therapy, and patients whose tumors shrank even minimally exhibited favorable progression-free survival. Higher DpR at any cut-off line exhibited better progression-free survival than those with lower DpR. Fifteen patients experienced irAEs, with 13 of these patients experiencing irAEs within 3 months of treatment initiation. irAEs were associated with the efficacy of ICI doublet therapy, but efficacy could not be predicted based on early irAE experience. <b> <i>Conclusion:</i> </b> ETS-high, DpR-high, and irAEs might be associated with favorable responses to nivolumab plus ipilimumab. As a predictor of efficacy at an early phase, ETS >0% could be a deciding factor for continuing ICI doublet therapy. </p><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d3734252e264">We studied the usefulness of evaluating early tumor shrinkage (ETS) as an efficacy predictor in patients with inoperable or recurrent esophageal cancer treated with nivolumab plus ipilimumab therapy. The immune checkpoint inhibitor (ICI) doublet therapy has been administered since 2022, and there are still not many patients who received this treatment all over the world. It is necessary to find well-responders to this treatment as soon as possible to improve outcomes and consider therapeutic strategies. We analyzed tumor shrinkage and clinicopathologic features in patients with inoperable or recurrent esophageal cancer treated with the treatment. ETS was defined as the percent decrease in the sum of the largest diameter of the target lesions at first evaluation after treatment initiation compared to that at baseline. Regarding ETS, those whose tumors shrank even minimally had favorable progression-free survival. Immune-related adverse events were also associated with the sensitivity and efficacy of ICI doublet therapy, but to find the efficacy at an early phase, ETS could be a decision-making factor for predicting the efficacy and continuation of ICI doublet therapy. </p>
Replied in thread
Public *
franebleu

@megatronicthronbanks @VedaDalsette @WatchForBones @idoubtit @megatronicthronbanks
For the Mosuo, in Nepal's vastness, the absence of the norms of sedentarized marriage and male domination may have contributed to society's evolution towards peacefulness.

Male domination + individualism may be significant factors favoring violence and preventing societies evolution towards peace and maturity.

researchgate.net/publication/3

Woman holding a cardboard in a general strike. "I am no longer accepting the things I cannot change. I am changing the things I cannot accept"
#Patriarchy#MaleDomination#RevolutionWontBeMasculinized
Public
The Times Of Update

Narayana Health, VC signs W Health Ventures to launch Cancer Attention Clinics timesofupdate.com/narayana-hea The Multiespecialty hospital chain launched Everhope Oncology, a joint venture with the risk capital firm focused on Healthtech W Health Ventures and Venture Studio 2070 Health, with a seed investment of $ 10 million. Everhope will establish nursery centers th… #cancer #CancerCare #CancerCareClinics #Health #HealthCare #NarayanaHealth #oncology #SignatureVC #WHealth

The Times of Update – Global News & In-Depth Analysis · Narayana Health, VC Signs W Health Ventures To Launch Cancer Attention Clinics - The Times Of Update
Public *
franebleu

Memes associated to the judgement element "Does it save lives ?" :

Useful meme :
Put a mask when there's a massive epidemic. (saves lives)

Neutral meme :
Use a tool to eat. (no big deal if you have clean hands)

Harmful meme :
It is impossible to put Elon Musk in prison immediately for the rest of his life, and it is impossible to seize his whole wealth and redistribute it to each US citizen through public services. (costs lives)

#Oncology
#NeutralizeAndRecycleBillionaires
#HealEarth
#Health

" - But Daddy... Then Earth and Moon are like some giant intelligent organism ? " " " - Huh... Yeah. " " - Then... what are billionaires ?" " - Hmmm... Tumors ?" #HEALEARTH Picture of Earth with rainbow colors and a massive purplish cancerous tumor in the background.
Public
Calishat

#cancer #oncology #medicine #science #research #AI

'Researchers at King’s have launched a first-of-its-kind dashboard that collates and drills down into more than a thousand AI and cancer studies, providing a wide-ranging overview of AI’s increasingly important role in tackling the disease.'

kcl.ac.uk/news/launch-of-first

King's College London · Launch of first online dashboard for AI and cancer papers to accelerate AI adoption in the clinicResearchers at King’s have launched a first-of-its-kind dashboard that collates and drills down into more than a thousand AI and cancer studies, providing a wide-ranging overview of AI’s increasingly important role in tackling the disease.
Public
ResearchBuzz: Firehose

King’s College London: Launch of first online dashboard for AI and cancer papers to accelerate AI adoption in the clinic. “Researchers at King’s have launched a first-of-its-kind dashboard that collates and drills down into more than a thousand AI and cancer studies, providing a wide-ranging overview of AI’s increasingly important role in tackling the disease.”

https://rbfirehose.com/2025/03/16/kings-college-london-launch-of-first-online-dashboard-for-ai-and-cancer-papers-to-accelerate-ai-adoption-in-the-clinic/

ResearchBuzz: Firehose | Individual posts from ResearchBuzz · King’s College London: Launch of first online dashboard for AI and cancer papers to accelerate AI adoption in the clinic | ResearchBuzz: Firehose
More from ResearchBuzz: Firehose
#ai#aiassisted#cancer
SearchLive feeds
About